TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01342185
Drug: Diammonium glycyrrhizinate Capsules
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
Study: NCT02459457
Drug: Paclitaxel and Fluorouracil
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients get Paclitaxel and Fluorouracil according to protocol
Study: NCT00477490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
Study: NCT00743587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
Study: NCT02498782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04230122
Drug: LY3478006 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04230122
Drug: LY3478006 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04230122
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00743587
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 1 x 500mg enteric-coated
Study: NCT00902746
Drug: NPC-01
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point.
Study: NCT03598153
Drug: Shujinjianyao Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
Study: NCT01546532
Drug: RLX030
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLX030 as intravenous infusion for 24 hours.
Study: NCT01546532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Placebo over 24 hours
Study: NCT01190059
Drug: Ex vivo lung perfusion with Steen Solution™
Approvals — FDA: no, EMA: no, PMDA: no
Description: The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
Study: NCT01780259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
Study: NCT02623751
Drug: KHK2375
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily.
Study: NCT01011868
Drug: BI 10773 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 10773 placebo
Study: NCT01275781
Drug: [14C]-AZD9742
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous over 2 hours
Study: NCT02649504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
Study: NCT02879526
Drug: C-CPT
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
Study: NCT00167206
Drug: Cyclophosphamide, Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
Study: NCT01670773
Drug: Salsalate + DHA
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01670773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01316146
Drug: CAR.CD30 T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc.
Study: NCT04816123
Drug: [14C]Donafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
Study: NCT01469520
Drug: Epivir®, Retrovir® and Viramune®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
Study: NCT03019419
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02570997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered.
Study: NCT01449955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive
Study: NCT03010579
Drug: iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
Study: NCT03008798
Drug: Herbal Medicine C-117
Approvals — FDA: no, EMA: no, PMDA: no
Description: C117 formula including 2 herbals and 2 insects
Study: NCT03008798
Drug: The Placebo of Herbal Medicine C-117
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03095469
Drug: 0.9%NaCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
Study: NCT00002539
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03548220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching AG-348 tablets, administered to maintain the blind.
Study: NCT00501657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg mane for 2 days
Study: NCT00611975
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
Study: NCT03468790
Drug: CMAB007
Approvals — FDA: no, EMA: no, PMDA: no
Description: the study drug
Study: NCT03468790
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active components
Study: NCT04083963
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
Study: NCT04083963
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
Study: NCT00358215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT03078569
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with testosterone gel
Study: NCT01340248
Drug: Dilatrend 64mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting
Study: NCT01184001
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
Study: NCT01184001
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
Study: NCT00143104
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03408405
Drug: Acthar Gel 80 UNT/ML Injectable Solution
Normalized name: Acthar Gel 80 UNT/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
Study: NCT01385748
Drug: Placebo Lauriad®
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
Study: NCT00233480
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo Qd x 3 months
Study: NCT02262611
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02262611
Drug: MicardisPlus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02774811
Drug: Prostaglandin analogue
Normalized name: Prostaglandin analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy
Study: NCT00003534
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04204382
Drug: Compound Kushen Injection（CKI）
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
Study: NCT00557557
Drug: Drug: 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
Study: NCT03388268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar liquid manufactured to mimic oral vancomycin 125mg
Study: NCT03507543
Drug: IMP4297
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study: NCT00079794
Drug: mistletoe
Normalized name: MISTLETOE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01681277
Drug: Placebo to BI 113608 PIB bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for oral solution
Study: NCT02858453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appearance and weight matched placebo tablets
Study: NCT01200342
Drug: Genasense
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
Study: NCT01475305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
Study: NCT01475305
Drug: MEDI-557
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
Study: NCT02385058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally once starting on Day 21.
Study: NCT00557908
Drug: VWF/FVIII products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses
Study: NCT01516255
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
Study: NCT01516255
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
Study: NCT03752177
Drug: LY3415244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00725270
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02673632
Drug: Merional ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
Study: NCT01423591
Drug: inactive powder
Normalized name: collagen,activated Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
Study: NCT02779114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
Study: NCT00087776
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00538148
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02248818
Drug: AZD8108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AZD8108 Single or Multiple doses administered orally as a solution.
Study: NCT02248818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
Study: NCT02961855
Drug: anesthesics plus antiinflammatory, CLIFE1
Approvals — FDA: no, EMA: no, PMDA: no
Description: anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
Study: NCT04425590
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg tablet once daily
Study: NCT04425590
Drug: Vit B12
Normalized name: vit B12/pyridoxine/thiamine ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit B12 100 mg tablet three times daily
Study: NCT02961855
Drug: local anesthesics, CLIFE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
Study: NCT01955187
Drug: CYCLOPHOSPHAMIDE
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
Study: NCT01986088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00527787
Drug: PN400 (VIMOVO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
Study: NCT00527787
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (500 mg) dosed twice daily (bid) orally
Study: NCT00218608
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
Study: NCT02179177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01981005
Drug: RO5424802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses followed by IV or oral administration of a 14C-labeled tracer
Study: NCT03098563
Drug: Blinded study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
Study: NCT04324905
Drug: HIP1802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT04324905
Drug: HGP1705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT00964262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plcacebo of each doasage, single subcutanoeus injection
Study: NCT02484482
Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03748979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 Placebo
Study: NCT00519675
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01541852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice daily
Study: NCT02393742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01016262
Drug: MAX-002
Normalized name: heparinoids 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
Study: NCT01016262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
Study: NCT02132832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Study: NCT00919191
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel 0.04% used once daily in a split-face model
Study: NCT00002475
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03733353
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03733353
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01821404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Study: NCT00039663
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00441051
Drug: Diclofenac sodium 1mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03840005
Drug: Ursonorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid
Study: NCT02979249
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: for one year
Study: NCT00338962
Drug: desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg per day
Study: NCT00338962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01093443
Drug: ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFSH with GnRH antagonists
Study: NCT01224977
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin 500 mg 3/week for 3 months
Study: NCT03815812
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
Study: NCT00259350
Drug: Skin disinfection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02406261
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg simvastatin will be administered orally as 1 × 20-mg tablet
Study: NCT00914745
Drug: Ointment
Normalized name: Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
Study: NCT00825539
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no